Tarceva OSI/Genentech - Treatment for Non-Small Cell Lung Cancer (NSCLC)

Tarceva is a Human Epidermal Growth Factor Receptor Type 1/Epidermal Growth Factor Receptor (HER1/EGFR) tyrosine kinase inhibitor indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.

Posted: November 2004

Related Articles:

Tarceva (erlotinib) FDA Approval History

View comments

Hide
(web1)